Method for treating epstein-barr virus—positive cancer with immunotherapy
A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analyzing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT. Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT.
1. A method of treating an Epstein-Barr Virus (EBV)-positive cancer in a patient by adoptive cell transfer (ACT) of EBV-specific CTLs, the method comprising:
(i) determining in a blood sample, or a plasma or serum sample derived from a blood sample obtained from the patient:
(a) the ratio of the level of CXCL10 and/or CCL20 to the level of IFNγ, and
(b) the ratio of the level of EBV nucleic acid to the level of IFNγ, and
(ii) if said patient is determined to have (a) a ratio of the log 10-transformed level of CXCL10 in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 2.5 and/or a ratio of the log 10-transformed level of CCL20 in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 1.0, and (b) a ratio of the log 10-transformed level of EBV nucleic acid in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 3.0, administering one or more doses of EBV-specific CTLs to the patient.
2. The method of claim 1 , wherein the method additionally comprises an initial step of administering a dose of EBV-specific CTLs to the patient.
3. The method of claim 2 , wherein the blood sample, or a plasma or serum sample derived from a blood sample is obtained from the patient within a period of 4 weeks after the initial step of administering a dose of EBV-specific CTLs to the patient.
4. The method of claim 1 , wherein the EBV-positive cancer is selected from EBV-positive nasopharyngeal carcinoma (NPC), EBV-positive liver cancer, EBV-positive lung cancer, and EBV-positive gastric cancer.
5. The method of claim 1 , wherein the EBV-positive cancer is EBV-positive NPC.
6. A method of treating an Epstein-Barr Virus (EBV)-positive cancer in a patient by adoptive cell transfer (ACT) of EBV-specific CTLs, comprising:
(i) determining in a blood sample, or a plasma or serum sample derived from a blood sample obtained from the patient:
(a) the ratio of the level of CXCL10 and/or CCL20 to the level of IFNγ, and
(b) the ratio of the level of EBV nucleic acid to the level of IFNγ;
(ii) based on step (i), predicting whether the patient will be a long-term survivor on treatment of the EBV-positive cancer by ACT of EBV-specific CTLs, wherein detection of (a) a ratio of the log 10-transformed level of CXCL10 in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 2.5 and/or a ratio of the log 10-transformed level of CCL20 in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 1.0, and (b) a ratio of the log 10-transformed level of EBV nucleic acid in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 3.0 is predictive of long-term patient survival on treatment of the EBV-positive cancer by ACT of EBV-specific CTLs;
(iii) selecting a patient predicted to be a long-term survivor on treatment of the EBV-positive cancer by ACT of EBV-specific CTLs for treatment by ACT of EBV-specific CTLs; and
(iv) administering one or more doses of EBV-specific CTLs to the patient selected in step (iii).
7. The method of claim 6 , wherein the method additionally comprises an initial step of administering a dose of EBV-specific CTLs to the patient.
8. The method of claim 7 , wherein the blood sample, or a plasma or serum sample derived from a blood sample is obtained from the patient within a period of 4 weeks after the initial step of administering a dose of EBV-specific CTLs to the patient.
9. The method of claim 6 , wherein the EBV-positive cancer is selected from EBV-positive nasopharyngeal carcinoma (NPC), EBV-positive liver cancer, EBV-positive lung cancer, and EBV-positive gastric cancer.
10. The method of claim 6 , wherein the EBV-positive cancer is EBV-positive NPC.
11. A method of treating an Epstein-Barr Virus (EBV)-positive cancer in a patient by adoptive cell transfer (ACT) of EBV-specific CTLs, comprising:
(i) administering a dose of EBV-specific CTLs to the patient;
(ii) determining in a blood sample, or a plasma or serum sample derived from a blood sample obtained from the patient:
(a) the ratio of the level of CXCL10 and/or CCL20 to the level of IFNγ, and
(b) the ratio of the level of EBV nucleic acid to the level of IFNγ;
(iii) based on step (ii), predicting whether the patient will be a long-term survivor on treatment of the EBV-positive cancer by ACT of EBV-specific CTLs, wherein detection of (a) a ratio of the log 10-transformed level of CXCL10 in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 2.5 and/or a ratio of the log 10-transformed level of CCL20 in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 1.0, and (b) a ratio of the log 10-transformed level of EBV nucleic acid in pg/ml to the log 10-transformed level of IFNγ in pg/ml of less than 3.0 is predictive of long-term patient survival on treatment of the EBV-positive cancer by ACT of EBV-specific CTLs;
(iv) selecting a patient predicted to be a long-term survivor on treatment of the EBV-positive cancer by ACT of EBV-specific CTLs for treatment by ACT of EBV-specific CTLs; and
(v) administering one or more doses of EBV-specific CTLs to the patient selected in step (iv).
12. The method of claim 11 , wherein the blood sample, or a plasma or serum sample derived from a blood sample is obtained from the patient within a period of 4 weeks after administering a dose of EBV-specific CTLs to the patient in step (i).
13. The method of claim 11 , wherein the EBV-positive cancer is selected from EBV-positive nasopharyngeal carcinoma (NPC), EBV-positive liver cancer, EBV-positive lung cancer, and EBV-positive gastric cancer.
14. The method of claim 11 , wherein the EBV-positive cancer is EBV-positive NPC.